Japan Approves Novavax as 4th Covid Vaccine Amid New Surge
The Novavax Inc. Nuvaxovid Covid-19 vaccine.
Photographer: Liesa Johannssen-Koppitz/BloombergThis article is for subscribers only.
Tokyo (AP) -- Japan’s health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to combat the infections as the country sees signs of a resurgence led by a subvariant of fast-spreading omicron.
The ministry approval comes the day after its experts panel endorsed use of Novavax's protein vaccine, which is designed with similar technology used to fight diseases such as the flu and hepatitis B, for the first two shots and a booster.